COMMUNIQUÉS West-GlobeNewswire

Annexon Biosciences to Present at the Jefferies London Healthcare Conference
13/11/2024
BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today [...]
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
13/11/2024
AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society for Immunotherapy of [...]
STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
13/11/2024
HORSHAM, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
13/11/2024
SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief [...]
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
13/11/2024
Generated $48.1 million in XDEMVY ® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare [...]
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
13/11/2024
– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has [...]
The Ensign Group to Present at the Stephens Annual Investment Conference on November 20, 2024
13/11/2024
SAN JUAN CAPISTRANO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results
13/11/2024
Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for one to two DC [...]
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
13/11/2024
SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Glass House Brands Reports Record Setting Third Quarter 2024 Financial Results
13/11/2024
- Glass House achieved record setting results for over 10 key metrics, including consolidated revenue and gross profit, wholesale biomass revenue, retail revenue, biomass production and cultivation cost per pound - [...]
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
13/11/2024
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor [...]
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
13/11/2024
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, [...]
Alvotech Reports Financial Results for the First Nine Months of 2024
13/11/2024
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 million Product revenues in the first nine months of 2024 [...]
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
12/11/2024
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion ( [...]
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
12/11/2024
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today [...]
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
12/11/2024
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/11/2024
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
12/11/2024
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Company’s annual and [...]
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
12/11/2024
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 [...]

Pages